Literature DB >> 21940217

Targeting B cell responses in universal influenza vaccine design.

Kaval Kaur1, Meghan Sullivan, Patrick C Wilson.   

Abstract

Since its first administration in the 1940s, the influenza vaccine has provided tremendous relief against influenza infections. However, time has revealed the ultimate limit of the vaccine and the call for its reinvention has now come, just as we are beginning to appreciate the antibody immune responses vital in preventing infections. New strategies to design the influenza vaccine rely on selectively inducing broadly neutralizing antibodies that are specific for highly conserved viral epitopes. Such approaches take us away from the limited range of protection provided by current seasonal influenza vaccines and towards a future with a pan-influenza vaccine capable of providing universal strain coverage.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940217      PMCID: PMC3212832          DOI: 10.1016/j.it.2011.08.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  57 in total

1.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

2.  Activation of influenza A viruses by trypsin treatment.

Authors:  H D Klenk; R Rott; M Orlich; J Blödorn
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

3.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

4.  Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Authors:  Andres G Grandea; Ole A Olsen; Thomas C Cox; Mark Renshaw; Philip W Hammond; Po-Ying Chan-Hui; Jennifer L Mitcham; Witold Cieplak; Shaun M Stewart; Michael L Grantham; Andrew Pekosz; Maki Kiso; Kyoko Shinya; Masato Hatta; Yoshihiro Kawaoka; Matthew Moyle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-01       Impact factor: 11.205

5.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

Review 7.  Composition and functions of the influenza fusion peptide.

Authors:  Karen J Cross; William A Langley; Rupert J Russell; John J Skehel; David A Steinhauer
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

8.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

9.  The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid.

Authors:  W P Burmeister; R W Ruigrok; S Cusack
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  40 in total

Review 1.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.

Authors:  Nitin Verma; Milena Dimitrova; Donald M Carter; Corey J Crevar; Ted M Ross; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

3.  Detection of influenza A/H1N1-specific human IgG-secreting B cells in older adults by ELISPOT assay.

Authors:  Scott D Painter; Iana H Haralambieva; Inna G Ovsyannikova; Diane E Grill; Gregory A Poland
Journal:  Viral Immunol       Date:  2014-03       Impact factor: 2.257

4.  High preexisting serological antibody levels correlate with diversification of the influenza vaccine response.

Authors:  Sarah F Andrews; Kaval Kaur; Noel T Pauli; Min Huang; Yunping Huang; Patrick C Wilson
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

5.  Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.

Authors:  Carole J Henry Dunand; Paul E Leon; Kaval Kaur; Gene S Tan; Nai-Ying Zheng; Sarah Andrews; Min Huang; Xinyan Qu; Yunping Huang; Marlene Salgado-Ferrer; Irvin Y Ho; William Taylor; Rong Hai; Jens Wrammert; Rafi Ahmed; Adolfo García-Sastre; Peter Palese; Florian Krammer; Patrick C Wilson
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

6.  High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination.

Authors:  Yann-Chong Tan; Lisa K Blum; Sarah Kongpachith; Chia-Hsin Ju; Xiaoyong Cai; Tamsin M Lindstrom; Jeremy Sokolove; William H Robinson
Journal:  Clin Immunol       Date:  2014-01-09       Impact factor: 3.969

7.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

8.  Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection.

Authors:  Suman R Das; Scott E Hensley; William L Ince; Christopher B Brooke; Anju Subba; Mark G Delboy; Gustav Russ; James S Gibbs; Jack R Bennink; Jonathan W Yewdell
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

9.  Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.

Authors:  Attapon Kamlangdee; Brock Kingstad-Bakke; Jorge E Osorio
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

Review 10.  Emerging roles for protein S-palmitoylation in immunity from chemical proteomics.

Authors:  Jacob S Yount; Mingzi M Zhang; Howard C Hang
Journal:  Curr Opin Chem Biol       Date:  2013-01-14       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.